San Diego, CA--May 23, 2011--Mentor Capital, Inc. (Pink Sheets:MNTR) is scheduled to meet and screen leading-edge cancer fighting companies for potential investment at the June 3-7, 2011 ASCO conference in Chicago, IL. At the Chicago cancer conference, Mentor seeks to advance the commitment of the remaining $120 Million in its current authorization. The company is experiencing that the typical requested cancer funding increment is $10 Million, and often is to be applied to support a round of FDA drug development trials.

Mentor Capital, which only is acquiring and investing in cancer related companies, initiated its current round of funding May 5, 2011. The company currently holds $2.50 per Mentor share in cancer assets from twelve companies. Management seeks to weight its investments so that shareholders support the best medical science in the battle against cancer. Typical cancer investments can be tracked through updates and summaries of the several smaller stock purchases made for the Cancer Immunotherapy Index presented at www.MentorCapital.com.

The 47th Annual American Society of Clinical Oncology (ASCO) conference has 15,000 physician attendees and is an ideal forum to advance the allocation of Mentor funding commitments. The 5,000 expected exhibitors and presenting researchers represent the forefront of cancer development. Mentor feels its key competitive advantage is the ability of management to selectively recognize and align shareholder funding with the best medical science in the cancer space.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.


__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.


Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

 ↑ Back to Top